Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Intensive Care
Published in: Annals of Intensive Care 1/2017

Open Access 01-12-2017 | Review

Immunohaemostasis: a new view on haemostasis during sepsis

Authors: Xavier Delabranche, Julie Helms, Ferhat Meziani

Published in: Annals of Intensive Care | Issue 1/2017

Login to get access

Abstract

Host infection by a micro-organism triggers systemic inflammation, innate immunity and complement pathways, but also haemostasis activation. The role of thrombin and fibrin generation in host defence is now recognised, and thrombin has become a partner for survival, while it was seen only as one of the “principal suspects” of multiple organ failure and death during septic shock. This review is first focused on pathophysiology. The role of contact activation system, polyphosphates and neutrophil extracellular traps has emerged, offering new potential therapeutic targets. Interestingly, newly recognised host defence peptides (HDPs), derived from thrombin and other “coagulation” factors, are potent inhibitors of bacterial growth. Inhibition of thrombin generation could promote bacterial growth, while HDPs could become novel therapeutic agents against pathogens when resistance to conventional therapies grows. In a second part, we focused on sepsis-induced coagulopathy diagnostic challenge and stratification from “adaptive” haemostasis to “noxious” disseminated intravascular coagulation (DIC) either thrombotic or haemorrhagic. Besides usual coagulation tests, we discussed cellular haemostasis assessment including neutrophil, platelet and endothelial cell activation. Then, we examined therapeutic opportunities to prevent or to reduce “excess” thrombin generation, while preserving “adaptive” haemostasis. The fail of international randomised trials involving anticoagulants during septic shock may modify the hypothesis considering the end of haemostasis as a target to improve survival. On the one hand, patients at low risk of mortality may not be treated to preserve “immunothrombosis” as a defence when, on the other hand, patients at high risk with patent excess thrombin and fibrin generation could benefit from available (antithrombin, soluble thrombomodulin) or ongoing (FXI and FXII inhibitors) therapies. We propose to better assess coagulation response during infection by an improved knowledge of pathophysiology and systematic testing including determination of DIC scores. This is one of the clues to allocate the right treatment for the right patient at the right moment.
Appendix
Available only for authorised users
Literature
1.
2.
Schmaier AH. The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities. J Thromb Haemost. 2016;14(1):28–39.PubMedCrossRef
3.
Long AT, Kenne E, Jung R, Fuchs TA, Renne T. Contact system revisited: an interface between inflammation, coagulation, and innate immunity. J Thromb Haemost. 2016;14(3):427–37.PubMedCrossRef
4.
Lerolle N, Carlotti A, Melican K, et al. Assessment of the interplay between blood and skin vascular abnormalities in adult purpura fulminans. Am J Respir Crit Care Med. 2013;188(6):684–92.PubMedCrossRef
5.
Arman M, Krauel K, Tilley DO, et al. Amplification of bacteria-induced platelet activation is triggered by FcγRIIA, integrin αIIbβ3, and platelet factor 4. Blood. 2014;123(20):3166–74.PubMedPubMedCentralCrossRef
6.
7.
Nieuwland R, Berckmans RJ, McGregor S, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood. 2000;95(3):930–5.PubMed
8.
Delabranche X, Boisrame-Helms J, Asfar P, et al. Microparticles are new biomarkers of septic shock-induced disseminated intravascular coagulopathy. Intensive Care Med. 2013;39(10):1695–703.PubMedCrossRef
9.
10.
11.
12.
Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580–637.PubMedCrossRef
13.
Iba T, Gando S, Thachil J. Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan. J Thromb Haemost. 2014;12(7):1010–9.PubMedCrossRef
14.
Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13(1):34–45.PubMedCrossRef
15.
Claushuis TA, de Stoppelaar SF, Stroo I, et al. Thrombin contributes to protective immunity in pneumonia-derived sepsis via fibrin polymerization and platelet-neutrophil interactions. J Thromb Haemost. 2017;15(4):744–57.PubMedCrossRef
16.
17.
van der Poll T, Herwald H. The coagulation system and its function in early immune defense. Thromb Haemost. 2014;112(4):640–8.PubMedCrossRef
18.
Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care. 2014;2(1):15.PubMedPubMedCentralCrossRef
19.
Gando S, Wada H, Thachil J. Scientific and Standardization Committee on DIC of the International Society on Thrombosis and Haemostasis (ISTH). Differentiating disseminated intravascular coagulation (DIC) with the fibrinolytic phenotype from coagulopathy of trauma and acute coagulopathy of trauma-shock (COT/ACOTS). J Thromb Haemost. 2013;11(5):826–35.PubMedCrossRef
20.
Gando S, Otomo Y. Local hemostasis, immunothrombosis, and systemic disseminated intravascular coagulation in trauma and traumatic shock. Crit Care. 2015;19:72.PubMedPubMedCentralCrossRef
21.
Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way? Crit Care Med. 2012;40(9):2704–8.PubMedCrossRef
22.
Levi M. The coagulant response in sepsis and inflammation. Hamostaseologie 2010; 30(1): 10–2, 4–6.
23.
24.
Versteeg HH, Heemskerk JW, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev. 2013;93(1):327–58.PubMedCrossRef
25.
Krem MM, Rose T, Di Cera E. Sequence determinants of function and evolution in serine proteases. Trends Cardiovasc Med. 2000;10(4):171–6.PubMedCrossRef
26.
Davidson CJ, Tuddenham EG, McVey JH. 450 million years of hemostasis. J Thromb Haemost. 2003;1(7):1487–94.PubMedCrossRef
27.
Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD. Interactions between coagulation and complement–their role in inflammation. Semin Immunopathol. 2012;34(1):151–65.PubMedCrossRef
28.
Berends ET, Kuipers A, Ravesloot MM, Urbanus RT, Rooijakkers SH. Bacteria under stress by complement and coagulation. FEMS Microbiol Rev. 2014;38(6):1146–71.PubMedCrossRef
29.
White GC 2nd. The partial thromboplastin time: defining an era in coagulation. J Thromb Haemost. 2003;1(11):2267–70.PubMedCrossRef
30.
Evans CE, Zhao YY. Impact of thrombosis on pulmonary endothelial injury and repair following sepsis. Am J Physiol Lung Cell Mol Physiol. 2017;312(4):L441–51.PubMedCrossRef
31.
Frick IM, Bjorck L, Herwald H. The dual role of the contact system in bacterial infectious disease. Thromb Haemost. 2007;98(3):497–502.PubMed
32.
33.
Kornberg A, Rao NN, Ault-Riche D. Inorganic polyphosphate: a molecule of many functions. Annu Rev Biochem. 1999;68:89–125.PubMedCrossRef
34.
Smith SA, Choi SH, Davis-Harrison R, et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood. 2010;116(20):4353–9.PubMedPubMedCentralCrossRef
35.
Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res. 2012;129(3):290–5.PubMedCrossRef
36.
Mitchell JL, Lionikiene AS, Georgiev G, et al. Polyphosphate colocalizes with factor XII on platelet-bound fibrin and augments its plasminogen activator activity. Blood. 2016;128(24):2834–45.PubMedPubMedCentralCrossRef
37.
38.
Verhoef JJ, Barendrecht AD, Nickel KF, et al. Polyphosphate nanoparticles on the platelet surface trigger contact system activation. Blood. 2017;129(12):1707–17.PubMedCrossRef
39.
Weitz JI, Fredenburgh JC. Platelet polyphosphate: the long and the short of it. Blood. 2017;129(12):1574–5.PubMedCrossRef
40.
Whyte CS, Chernysh IN, Domingues MM, et al. Polyphosphate delays fibrin polymerisation and alters the mechanical properties of the fibrin network. Thromb Haemost. 2016;116(5):897–903.PubMedPubMedCentralCrossRef
41.
42.
Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. Neutrophil function: from mechanisms to disease. Annu Rev Immunol. 2012;30:459–89.PubMedCrossRef
43.
44.
Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–5.PubMedCrossRef
45.
46.
Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol. 2010;191(3):677–91.PubMedPubMedCentralCrossRef
47.
Pilsczek FH, Salina D, Poon KK, et al. A novel mechanism of rapid nuclear neutrophil extracellular trap formation in response to Staphylococcus aureus. J Immunol. 2010;185(12):7413–25.PubMedCrossRef
48.
49.
Noubouossie DF, Whelihan MF, Yu YB, et al. In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps. Blood. 2017;129(8):1021–9.PubMedCrossRef
50.
Abrams ST, Zhang N, Dart C, et al. Human CRP defends against the toxicity of circulating histones. J Immunol. 2013;191(5):2495–502.PubMedCrossRef
51.
Smeesters PR, McMillan DJ, Sriprakash KS. The streptococcal M protein: a highly versatile molecule. Trends Microbiol. 2010;18(6):275–82.PubMedCrossRef
52.
McAdow M, Missiakas DM, Schneewind O. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun. 2012;4(2):141–8.PubMedPubMedCentralCrossRef
53.
Thomer L, Schneewind O, Missiakas D. Multiple ligands of von Willebrand factor-binding protein (vWbp) promote Staphylococcus aureus clot formation in human plasma. J Biol Chem. 2013;288(39):28283–92.PubMedPubMedCentralCrossRef
54.
Fitzgerald JR, Loughman A, Keane F, et al. Fibronectin-binding proteins of Staphylococcus aureus mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcγRIIa receptor. Mol Microbiol. 2006;59(1):212–30.PubMedCrossRef
55.
Imamura T, Tanase S, Szmyd G, Kozik A, Travis J, Potempa J. Induction of vascular leakage through release of bradykinin and a novel kinin by cysteine proteinases from Staphylococcus aureus. J Exp Med. 2005;201(10):1669–76.PubMedPubMedCentralCrossRef
56.
Wollein Waldetoft K, Svensson L, Morgelin M, et al. Streptococcal surface proteins activate the contact system and control its antibacterial activity. J Biol Chem. 2012;287(30):25010–8.PubMedPubMedCentralCrossRef
57.
Chung MC, Popova TG, Jorgensen SC, et al. Degradation of circulating von Willebrand factor and its regulator ADAMTS13 implicates secreted Bacillus anthracis metalloproteases in anthrax consumptive coagulopathy. J Biol Chem. 2008;283(15):9531–42.PubMedCrossRef
58.
Kastrup CJ, Boedicker JQ, Pomerantsev AP, et al. Spatial localization of bacteria controls coagulation of human blood by ‘quorum acting’. Nat Chem Biol. 2008;4(12):742–50.PubMedPubMedCentralCrossRef
59.
Sun H, Wang X, Degen JL, Ginsburg D. Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood. 2009;113(6):1358–64.PubMedPubMedCentralCrossRef
60.
Rivera J, Vannakambadi G, Hook M, Speziale P. Fibrinogen-binding proteins of Gram-positive bacteria. Thromb Haemost. 2007;98(3):503–11.PubMed
61.
Degen JL, Bugge TH, Goguen JD. Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost. 2007;5(Suppl 1):24–31.PubMedCrossRef
62.
Brissette CA, Haupt K, Barthel D, et al. Borrelia burgdorferi infection-associated surface proteins ErpP, ErpA, and ErpC bind human plasminogen. Infect Immun. 2009;77(1):300–6.PubMedCrossRef
63.
Barthel D, Singh B, Riesbeck K, Zipfel PF. Haemophilus influenzae uses the surface protein E to acquire human plasminogen and to evade innate immunity. J Immunol. 2012;188(1):379–85.PubMedCrossRef
64.
Pancholi V, Fischetti VA. alpha-enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci. J Biol Chem. 1998;273(23):14503–15.PubMedCrossRef
65.
Bergmann S, Rohde M, Chhatwal GS, Hammerschmidt S. Alpha-enolase of Streptococcus pneumoniae is a plasmin(ogen)-binding protein displayed on the bacterial cell surface. Mol Microbiol. 2001;40(6):1273–87.PubMedCrossRef
66.
Chung MC, Tonry JH, Narayanan A, et al. Bacillus anthracis interacts with plasmin(ogen) to evade C3b-dependent innate immunity. PLoS ONE. 2011;6(3):0018119.CrossRef
67.
Floden AM, Watt JA, Brissette CA. Borrelia burgdorferi enolase is a surface-exposed plasminogen binding protein. PLoS ONE. 2011;6(11):8.CrossRef
68.
Bisno AL, Brito MO, Collins CM. Molecular basis of group A streptococcal virulence. Lancet Infect Dis. 2003;3(4):191–200.PubMedCrossRef
69.
Verhamme IM, Panizzi PR, Bock PE. Pathogen activators of plasminogen. J Thromb Haemost. 2015;13(1):12939.
70.
Wiles KG, Panizzi P, Kroh HK, Bock PE. Skizzle is a novel plasminogen- and plasmin-binding protein from Streptococcus agalactiae that targets proteins of human fibrinolysis to promote plasmin generation. J Biol Chem. 2010;285(27):21153–64.PubMedPubMedCentralCrossRef
71.
Stathopoulos C. Structural features, physiological roles, and biotechnological applications of the membrane proteases of the OmpT bacterial endopeptidase family: a micro-review. Membr Cell Biol. 1998;12(1):1–8.PubMed
72.
Haiko J, Suomalainen M, Ojala T, Lahteenmaki K, Korhonen TK. Invited review: breaking barriers—attack on innate immune defences by omptin surface proteases of enterobacterial pathogens. Innate Immun. 2009;15(2):67–80.PubMedCrossRef
73.
Korhonen TK, Haiko J, Laakkonen L, Jarvinen HM, Westerlund-Wikstrom B. Fibrinolytic and coagulative activities of Yersinia pestis. Front Cell Infect Microbiol. 2013;3:35.PubMedPubMedCentralCrossRef
74.
Korhonen TK. Fibrinolytic and procoagulant activities of Yersinia pestis and Salmonella enterica. J Thromb Haemost. 2015;13(1):12932.
75.
Ooe A, Kida M, Yamazaki T, et al. Common mutation of plasminogen detected in three Asian populations by an amplification refractory mutation system and rapid automated capillary electrophoresis. Thromb Haemost. 1999;82(4):1342–6.PubMed
76.
Thomassin JL, Brannon JR, Gibbs BF, Gruenheid S, Le Moual H. OmpT outer membrane proteases of enterohemorrhagic and enteropathogenic Escherichia coli contribute differently to the degradation of human LL-37. Infect Immun. 2012;80(2):483–92.PubMedPubMedCentralCrossRef
77.
Bengtson SH, Sanden C, Morgelin M, et al. Activation of TAFI on the surface of Streptococcus pyogenes evokes inflammatory reactions by modulating the kallikrein/kinin system. J Innate Immun. 2009;1(1):18–28.PubMedCrossRef
78.
Mook-Kanamori BB, Valls Seron M, Geldhoff M, et al. Thrombin-activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis. J Thromb Haemost. 2015;13(11):2076–86.PubMedCrossRef
79.
Akesson P, Herwald H, Rasmussen M, et al. Streptococcal inhibitor of complement-mediated lysis (SIC): an anti-inflammatory virulence determinant. Microbiology. 2010;156(Pt 12):3660–8.PubMedCrossRef
80.
Frick IM, Shannon O, Akesson P, et al. Antibacterial activity of the contact and complement systems is blocked by SIC, a protein secreted by Streptococcus pyogenes. J Biol Chem. 2011;286(2):1331–40.PubMedCrossRef
81.
Itoh S, Yokoyama R, Kamoshida G, et al. Staphylococcal superantigen-like protein 10 (SSL10) inhibits blood coagulation by binding to prothrombin and factor Xa via their gamma-carboxyglutamic acid (Gla) domain. J Biol Chem. 2013;288(30):21569–80.PubMedPubMedCentralCrossRef
82.
Yount NY, Yeaman MR. Peptide antimicrobials: cell wall as a bacterial target. Ann N Y Acad Sci. 2013;1277:127–38.PubMedCrossRef
83.
Yount NY, Yeaman MR. Emerging themes and therapeutic prospects for anti-infective peptides. Annu Rev Pharmacol Toxicol. 2012;52:337–60.PubMedCrossRef
84.
Kasetty G, Papareddy P, Kalle M, et al. The C-terminal sequence of several human serine proteases encodes host defense functions. J Innate Immun. 2011;3(5):471–82.PubMedCrossRef
85.
Papareddy P, Rydengard V, Pasupuleti M, et al. Proteolysis of human thrombin generates novel host defense peptides. PLoS Pathog. 2010;6(4):1000857.CrossRef
86.
Kalle M, Papareddy P, Kasetty G, et al. Host defense peptides of thrombin modulate inflammation and coagulation in endotoxin-mediated shock and Pseudomonas aeruginosa sepsis. PLoS ONE. 2012;7(12):13.CrossRef
87.
Kalle M, Papareddy P, Kasetty G, et al. Proteolytic activation transforms heparin cofactor II into a host defense molecule. J Immunol. 2013;190(12):6303–10.PubMedPubMedCentralCrossRef
88.
Kalle M, Papareddy P, Kasetty G, et al. A peptide of heparin cofactor II inhibits endotoxin-mediated shock and invasive Pseudomonas aeruginosa infection. PLoS ONE. 2014;9(7):e102577.PubMedPubMedCentralCrossRef
89.
Papareddy P, Kalle M, Bhongir RK, Morgelin M, Malmsten M, Schmidtchen A. Antimicrobial effects of helix D-derived peptides of human antithrombin III. J Biol Chem. 2014;289(43):29790–800.PubMedPubMedCentralCrossRef
90.
Malmstrom E, Morgelin M, Malmsten M, et al. Protein C inhibitor–a novel antimicrobial agent. PLoS Pathog. 2009;5(12):18.CrossRef
91.
Rieger D, Assinger A, Einfinger K, Sokolikova B, Geiger M. Protein C inhibitor (PCI) binds to phosphatidylserine exposing cells with implications in the phagocytosis of apoptotic cells and activated platelets. PLoS ONE. 2014;9(7):e101794.PubMedPubMedCentralCrossRef
92.
Spero JA, Lewis JH, Hasiba U. Disseminated intravascular coagulation. Findings in 346 patients. Thromb Haemost. 1980;43(1):28–33.PubMed
93.
Dutt T, Toh CH. The Yin-Yang of thrombin and activated protein C. Br J Haematol. 2008;140(5):505–15.PubMedCrossRef
94.
Wada H, Thachil J, Di Nisio M, et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013;4(10):12155.
95.
96.
Lipsker D. Ischemic limb gangrene with pulses [Correspondance]. N Engl J Med. 2015;373(24):2385–6.PubMedCrossRef
97.
Shapiro NI, Schuetz P, Yano K, et al. The association of endothelial cell signaling, severity of illness, and organ dysfunction in sepsis. Crit Care. 2010;14(5):R182.PubMedPubMedCentralCrossRef
98.
Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 2006;107(2):528–34.PubMedCrossRef
99.
100.
101.
Warkentin TE, Pai M. Shock, acute disseminated intravascular coagulation, and microvascular thrombosis: is ‘shock liver’ the unrecognized provocateur of ischemic limb necrosis? J Thromb Haemost. 2016;14(2):231–5.PubMedCrossRef
102.
Delabranche X, Berger A, Boisrame-Helms J, Meziani F. Microparticles and infectious diseases. Med Mal Infect. 2012;42(8):335–43.PubMedCrossRef
103.
104.
105.
Okajima K, Uchiba M, Murakami K, Okabe H, Takatsuki K. Plasma levels of soluble E-selectin in patients with disseminated intravascular coagulation. Am J Hematol. 1997;54(3):219–24.PubMedCrossRef
106.
Koyama K, Madoiwa S, Nunomiya S, et al. Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study. Crit Care. 2014;18(1):R13.PubMedPubMedCentralCrossRef
107.
Rossi E, Sanz-Rodriguez F, Eleno N, et al. Endothelial endoglin is involved in inflammation: role in leukocyte adhesion and transmigration. Blood. 2012;16:16.
108.
Rossi E, Smadja DM, Boscolo E, et al. Endoglin regulates mural cell adhesion in the circulatory system. Cell Mol Life Sci. 2016;73(8):1715–39.PubMedCrossRef
109.
110.
Delabranche X, Quenot JP, Lavigne T, et al. Early detection of disseminated intravascular coagulation during septic shock: a multicentre prospective study. Crit Care Med. 2016;17:17.
111.
Guitton C, Gerard N, Sebille V, et al. Early rise in circulating endothelial protein C receptor correlates with poor outcome in severe sepsis. Intensive Care Med. 2011;37(6):950–6.PubMedPubMedCentralCrossRef
112.
Perez-Casal M, Downey C, Fukudome K, Marx G, Toh CH. Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood. 2005;105(4):1515–22.PubMedCrossRef
113.
Perez-Casal M, Thompson V, Downey C, et al. The clinical and functional relevance of microparticles induced by activated protein C treatment in sepsis. Crit Care. 2011;15(4):R195.PubMedPubMedCentralCrossRef
114.
Osterud B. Tissue factor expression in blood cells. Thromb Res. 2010;125(1):10.
115.
Stakos DA, Kambas K, Konstantinidis T, et al. Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction. Eur Heart J. 2015;36(22):1405–14.PubMedPubMedCentralCrossRef
116.
Gould TJ, Lysov Z, Liaw PC. Extracellular DNA and histones: double-edged swords in immunothrombosis. JJ Thromb Haemost. 2015;13(Suppl 1):S82–91.CrossRef
117.
Delabranche X, Stiel L, Severac F, et al. Evidence of netosis in septic shock-induced disseminated intravascular coagulation. Shock. 2017;47(3):313–7.PubMedCrossRef
118.
Stiel L, Delabranche X, Galoisy AC, et al. Neutrophil fluorescence: a new indicator of cell activation during septic shock-induced disseminated intravascular coagulation. Crit Care Med. 2016;44(11):e1132–6.PubMedCrossRef
119.
Lesesve JF, Martin M, Banasiak C, et al. Schistocytes in disseminated intravascular coagulation. Int J Lab Hematol. 2014;36(4):439–43.PubMedCrossRef
120.
Pfitzner SA, Dempfle CE, Matsuda M, Heene DL. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A. Thromb Haemost. 1997;78(3):1069–78.PubMed
121.
Cauchie P, Cauchie C, Boudjeltia KZ, et al. Diagnosis and prognosis of overt disseminated intravascular coagulation in a general hospital—meaning of the ISTH score system, fibrin monomers, and lipoprotein-C-reactive protein complex formation. Am J Hematol. 2006;81(6):414–9.PubMedCrossRef
122.
Dickneite G, Czech J, Keuper H. Formation of fibrin monomers in experimental disseminated intravascular coagulation and its inhibition by recombinant hirudin. Circ Shock. 1994;42(4):183–9.PubMed
123.
Gris JC, Faillie JL, Cochery-Nouvellon E, Lissalde-Lavigne G, Lefrant JY. ISTH overt disseminated intravascular coagulation score in patients with septic shock: automated immunoturbidimetric soluble fibrin assay vs. D-dimer assay. J Thromb Haemost. 2011;9(6):1252–5.PubMedCrossRef
124.
Gris JC, Bouvier S, Cochery-Nouvellon E, Faillie JL, Lissalde-Lavigne G, Lefrant JY. Fibrin-related markers in patients with septic shock: individual comparison of D-dimers and fibrin monomers impacts on prognosis. Thromb Haemost. 2011;106(6):1228–30.PubMedCrossRef
125.
Greenberg CS, Devine DV, McCrae KM. Measurement of plasma fibrin D-dimer levels with the use of a monoclonal antibody coupled to latex beads. Am J Clin Pathol. 1987;87(1):94–100.PubMedCrossRef
126.
Wilde JT, Kitchen S, Kinsey S, Greaves M, Preston FE. Plasma D-dimer levels and their relationship to serum fibrinogen/fibrin degradation products in hypercoagulable states. Br J Haematol. 1989;71(1):65–70.PubMedCrossRef
127.
Carr JM, McKinney M, McDonagh J. Diagnosis of disseminated intravascular coagulation. Role of D-dimer. Am J Clin Pathol. 1989;91(3):280–7.PubMedCrossRef
128.
Boisclair MD, Ireland H, Lane DA. Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Rev. 1990;4(1):25–40.PubMedCrossRef
129.
Boisclair MD, Lane DA, Wilde JT, Ireland H, Preston FE, Ofosu FA. A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin-antithrombin complex, D-dimer and fibrinogen/fibrin fragment E antigen. Br J Haematol. 1990;74(4):471–9.PubMedCrossRef
130.
Fourrier F, Jourdain M, Tournois A, Caron C, Goudemand J, Chopin C. Coagulation inhibitor substitution during sepsis. Intensive Care Med. 1995;21(2):S264–8.PubMedCrossRef
131.
Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 1992;101(3):816–23.PubMedCrossRef
132.
Gando S, Kameue T, Matsuda N, Hayakawa M, Hoshino H, Kato H. Serial changes in neutrophil-endothelial activation markers during the course of sepsis associated with disseminated intravascular coagulation. Thromb Res. 2005;116(2):91–100.PubMedCrossRef
133.
Hans GA, Besser MW. The place of viscoelastic testing in clinical practice. Br J Haematol. 2016;173(1):37–48.PubMedCrossRef
134.
Brenner T, Schmidt K, Delang M, et al. Viscoelastic and aggregometric point-of-care testing in patients with septic shock—cross-links between inflammation and haemostasis. Acta Anaesthesiol Scand. 2012;56(10):1277–90.PubMedCrossRef
135.
Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290(2):238–47.PubMedCrossRef
136.
Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286(15):1869–78.PubMedCrossRef
137.
Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366(22):2055–64.PubMedCrossRef
138.
Meziani F, Vincent JL, Gando S. Should all patients with sepsis receive anticoagulation? Yes. Intensive Care Med. 2017;43:452–4.PubMedCrossRef
139.
van der Poll T, Opal SM. Should all septic patients be given systemic anticoagulation? No. Intensive Care Med. 2017;43(3):455–7.PubMedCrossRef
140.
Kenne E, Renne T. Factor XII: a drug target for safe interference with thrombosis and inflammation. Drug Discov Today. 2014;19(9):1459–64.PubMedCrossRef
141.
Chen Z, Seiffert D, Hawes B. Inhibition of Factor XI activity as a promising antithrombotic strategy. Drug Discov Today. 2014;19(9):1435–9.PubMedCrossRef
142.
Labberton L, Kenne E, Renne T. New agents for thromboprotection. A role for factor XII and XIIa inhibition. Hamostaseologie. 2015;35(4):338–50.PubMedCrossRef
143.
Caliezi C, Zeerleder S, Redondo M, et al. C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med. 2002;30(8):1722–8.PubMedCrossRef
144.
Zeerleder S, Caliezi C, van Mierlo G, et al. Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. Clin Diag Lab Immunol. 2003;10(4):529–35.
145.
Igonin AA, Protsenko DN, Galstyan GM, et al. C1-esterase inhibitor infusion increases survival rates for patients with sepsis. Crit Care Med. 2012;40(3):770–7.PubMedCrossRef
146.
Barratt-Due A, Johansen HT, Sokolov A, et al. The role of bradykinin and the effect of the bradykinin receptor antagonist icatibant in porcine sepsis. Shock. 2011;36(5):517–23.PubMedCrossRef
147.
Pixley RA, De La Cadena R, Page JD, et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest. 1993;91(1):61–8.PubMedPubMedCentralCrossRef
148.
Worm M, Kohler EC, Panda R, et al. The factor XIIa blocking antibody 3F7: a safe anticoagulant with anti-inflammatory activities. Ann Transl Med. 2015;3(17):2305–5839.
149.
Tucker EI, Verbout NG, Leung PY, et al. Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. Blood. 2012;119(20):4762–8.PubMedPubMedCentralCrossRef
150.
Stroo I, Zeerleder S, Ding C, et al. Coagulation factor XI improves host defence during murine pneumonia-derived sepsis independent of factor XII activation. Thromb Haemost. 2017;117(8):1601–14.PubMedCrossRef
151.
Nakamura M, Takeuchi T, Kawahara T, et al. Simultaneous targeting of CD14 and factor XIa by a fusion protein consisting of an anti-CD14 antibody and the modified second domain of bikunin improves survival in rabbit sepsis models. Eur J Pharmacol. 2017;802:60–8.PubMedCrossRef
152.
Thiery-Antier N, Binquet C, Vinault S, et al. Is thrombocytopenia an early prognostic marker in septic shock? Crit Care Med. 2016;44(4):764–72.PubMed
153.
Tsirigotis P, Chondropoulos S, Frantzeskaki F, et al. Thrombocytopenia in critically ill patients with severe sepsis/septic shock: prognostic value and association with a distinct serum cytokine profile. J Crit Care. 2016;32:9–15.PubMedCrossRef
154.
Falcone M, Russo A, Farcomeni A, et al. Septic shock from community-onset pneumonia: is there a role for aspirin plus macrolides combination? Intensive Care Med. 2016;42(2):301–2.PubMedCrossRef
155.
Falcone M, Russo A, Cangemi R, et al. Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin. J Am Heart Assoc. 2015;4(1):e001595.PubMedPubMedCentralCrossRef
156.
Valerio-Rojas JC, Jaffer IJ, Kor DJ, Gajic O, Cartin-Ceba R. Outcomes of severe sepsis and septic shock patients on chronic antiplatelet treatment: a historical cohort study. Crit Care Res Pract. 2013;2013:782573.PubMedPubMedCentral
157.
Smith SA, Choi SH, Collins JN, Travers RJ, Cooley BC, Morrissey JH. Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation. Blood. 2012;120(26):5103–10.PubMedPubMedCentralCrossRef
158.
Travers RJ, Shenoi RA, Kalathottukaren MT, Kizhakkedathu JN, Morrissey JH. Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. Blood. 2014;124(22):3183–90.PubMedPubMedCentralCrossRef
159.
Heemskerk S, Masereeuw R, Moesker O, et al. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Critical care medicine. 2009;37(2):417–23.PubMedCrossRef
160.
Pickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care. 2012;16(1):R14.PubMedPubMedCentralCrossRef
161.
Su F, Brands R, Wang Z, et al. Beneficial effects of alkaline phosphatase in septic shock. Crit Care Med. 2006;34(8):2182–7.PubMedCrossRef
162.
Tunjungputri RN, Peters E, van der Ven A, de Groot PG, de Mast Q, Pickkers P. Human recombinant alkaline phosphatase inhibits ex vivo platelet activation in humans. Thromb Haemost. 2016;116(6):1111–21.PubMedCrossRef
163.
Lee S, Ku SK, Bae JS. Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption. Chem Biol Interact. 2016;256:266–73.PubMedCrossRef
164.
Brill A, Fuchs TA, Savchenko AS, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. Journal of thrombosis and haemostasis: JTH. 2012;10(1):136–44.PubMedPubMedCentralCrossRef
165.
Mai SH, Khan M, Dwivedi DJ, et al. Delayed but not early treatment with DNase reduces organ damage and improves outcome in a murine model of sepsis. Shock. 2015;44(2):166–72.PubMedCrossRef
166.
McDonald B, Davis RP, Kim SJ, et al. Platelets and neutrophil extracellular traps collaborate to promote intravascular coagulation during sepsis in mice. Blood. 2017;129(10):1357–67.PubMedCrossRef
167.
Laukova L, Konecna B, Babickova J, et al. Exogenous deoxyribonuclease has a protective effect in a mouse model of sepsis. Biomed Pharmacother. 2017;93:8–16.PubMedCrossRef
168.
Chrysanthopoulou A, Kambas K, Stakos D, et al. Interferon lambda1/IL-29 and inorganic polyphosphate are novel regulators of neutrophil-driven thromboinflammation. J Pathol. 2017;243(1):111–22.PubMedCrossRef
Metadata
Title
Immunohaemostasis: a new view on haemostasis during sepsis
Authors
Xavier Delabranche
Julie Helms
Ferhat Meziani
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Annals of Intensive Care / Issue 1/2017
Electronic ISSN: 2110-5820
DOI
https://doi.org/10.1186/s13613-017-0339-5

Other articles of this Issue 1/2017

Annals of Intensive Care 1/2017 Go to the issue

Research

Effect of HA330 resin-directed hemoadsorption on a porcine acute respiratory distress syndrome model

Research

Application of updated guidelines on diastolic dysfunction in patients with severe sepsis and septic shock

Research

Prone positioning in acute respiratory distress syndrome after abdominal surgery: a multicenter retrospective study

Research

Ultrasound assessment of rectus femoris and anterior tibialis muscles in young trauma patients

Research

Outcome of patients with septic shock and high-dose vasopressor therapy

Research

Validation of transpulmonary thermodilution variables in hemodynamically stable patients with heart diseases